China News Agency, Berlin, December 21 (Reporter Peng Dawei) Bayer of Germany and WuXi Biologics announced on the 21st that they have reached an acquisition transaction.
According to the agreement, WuXi Biologics will acquire Bayer's biologic drug stock plant in Wuppertal, Germany for approximately 150 million euros for the production of active ingredients in the new crown vaccine and other biological drugs.
Bayer, headquartered in Leverkusen, Germany, is one of the world's largest companies in the healthcare and agricultural sectors.
WuXi Biologics, which has three operating bases in Shanghai, Wuxi and Suzhou, China and is listed in Hong Kong, is an open biopharmaceutical technology platform that provides end-to-end R&D services for global biopharmaceutical companies and biotechnology companies.
This acquisition is WuXi Biologics' second acquisition of a pharmaceutical factory in Germany this year.
In April of this year, it completed the acquisition of Bayer's biologics plant (DP7) in Leverkusen, Germany.
WuXi Biologics said on the 21st that the acquired biologic drug stock solution plant (MFG19) covers an area of 30,000 square meters, including three 1,000-liter perfusion and six 2,000-liter processing production lines, as well as independent downstream supporting facilities, which will be further enhanced WuXi Biologics' global supply capacity for the new crown vaccine and other biological drugs.
The MFG19 and DP7 plants are expected to be put into production in 2021, providing strong support for WuXi Biologics' European production supply chain.
Both Bayer and WuXi Biologics stated that the transaction is subject to regulatory approval and is expected to be completed in the first half of 2021.
(Finish)